Eintrag weiter verarbeiten
A Prospective, Randomized, Masked, Placebo‐Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite
Gespeichert in:
| Zeitschriftentitel: | Journal of Veterinary Internal Medicine |
|---|---|
| Personen und Körperschaften: | , , , , |
| In: | Journal of Veterinary Internal Medicine, 30, 2016, 6, S. 1851-1857 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Zollers, B. Wofford, J.A. Heinen, E. Huebner, M. Rhodes, L. Zollers, B. Wofford, J.A. Heinen, E. Huebner, M. Rhodes, L. |
|---|---|
| author |
Zollers, B. Wofford, J.A. Heinen, E. Huebner, M. Rhodes, L. |
| spellingShingle |
Zollers, B. Wofford, J.A. Heinen, E. Huebner, M. Rhodes, L. Journal of Veterinary Internal Medicine A Prospective, Randomized, Masked, Placebo‐Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite General Veterinary |
| author_sort |
zollers, b. |
| spelling |
Zollers, B. Wofford, J.A. Heinen, E. Huebner, M. Rhodes, L. 0891-6640 1939-1676 Wiley General Veterinary http://dx.doi.org/10.1111/jvim.14607 <jats:sec><jats:title>Background</jats:title><jats:p>Reduced appetite is a common clinical sign in dogs. This study evaluated the effectiveness and safety of capromorelin oral solution, (ENTYCE<jats:sup>®</jats:sup>, Aratana Therapeutics, Leawood, KS) a new drug that is a ghrelin receptor agonist, for stimulation of appetite in dogs with reduced appetite.</jats:p></jats:sec><jats:sec><jats:title>Hypothesis/Objectives</jats:title><jats:p>Capromorelin will increase appetite, as measured by the owner's evaluation, over 4 days. An additional objective was to evaluate the safety of capromorelin at the labeled dose.</jats:p></jats:sec><jats:sec><jats:title>Animals</jats:title><jats:p>A total of 244 client‐owned dogs reported by owners to be inappetent for at least 2 days were enrolled, with 177 cases in the effectiveness analysis.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>In this prospective, randomized, masked, placebo‐controlled study, dogs were treated daily with capromorelin (3 mg/kg) oral solution (n = 121) or placebo oral solution (n = 56). Owners completed an evaluation of appetite at days 0 and 3 ± 1. Success was defined as improvement in appetite at day 3. Safety was evaluated by physical examination, clinical pathology, and monitoring adverse events and owner observations.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Capromorelin treatment improved appetite compared to placebo (68.6% and 44.6% treatment successes with 95% CI 59.7, 76.3 and 32.2, 57.8, respectively, <jats:italic>P </jats:italic>=<jats:italic> </jats:italic>.008). Mean body weight in capromorelin‐treated dogs increased compared to placebo‐treated dogs (1.8% with 95% CI 1.3, 2.3, and 0.1% with 95% CI 0.9, 1.1, respectively, <jats:italic>P </jats:italic><<jats:italic> </jats:italic>.001). Adverse reactions occurring in >5% of either group were diarrhea and vomiting.</jats:p></jats:sec><jats:sec><jats:title>Conclusions and Clinical Importance</jats:title><jats:p>Capromorelin oral solution is an effective treatment for stimulation of appetite in dogs and represents the first ghrelin receptor agonist shown to be effective for this indication.</jats:p></jats:sec> A Prospective, Randomized, Masked, Placebo‐Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite Journal of Veterinary Internal Medicine |
| doi_str_mv |
10.1111/jvim.14607 |
| facet_avail |
Online Free |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qdmltLjE0NjA3 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qdmltLjE0NjA3 |
| institution |
DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 |
| imprint |
Wiley, 2016 |
| imprint_str_mv |
Wiley, 2016 |
| issn |
0891-6640 1939-1676 |
| issn_str_mv |
0891-6640 1939-1676 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
zollers2016aprospectiverandomizedmaskedplacebocontrolledclinicalstudyofcapromorelinindogswithreducedappetite |
| publishDateSort |
2016 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Veterinary Internal Medicine |
| source_id |
49 |
| title |
A Prospective, Randomized, Masked, Placebo‐Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite |
| title_unstemmed |
A Prospective, Randomized, Masked, Placebo‐Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite |
| title_full |
A Prospective, Randomized, Masked, Placebo‐Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite |
| title_fullStr |
A Prospective, Randomized, Masked, Placebo‐Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite |
| title_full_unstemmed |
A Prospective, Randomized, Masked, Placebo‐Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite |
| title_short |
A Prospective, Randomized, Masked, Placebo‐Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite |
| title_sort |
a prospective, randomized, masked, placebo‐controlled clinical study of capromorelin in dogs with reduced appetite |
| topic |
General Veterinary |
| url |
http://dx.doi.org/10.1111/jvim.14607 |
| publishDate |
2016 |
| physical |
1851-1857 |
| description |
<jats:sec><jats:title>Background</jats:title><jats:p>Reduced appetite is a common clinical sign in dogs. This study evaluated the effectiveness and safety of capromorelin oral solution, (ENTYCE<jats:sup>®</jats:sup>, Aratana Therapeutics, Leawood, KS) a new drug that is a ghrelin receptor agonist, for stimulation of appetite in dogs with reduced appetite.</jats:p></jats:sec><jats:sec><jats:title>Hypothesis/Objectives</jats:title><jats:p>Capromorelin will increase appetite, as measured by the owner's evaluation, over 4 days. An additional objective was to evaluate the safety of capromorelin at the labeled dose.</jats:p></jats:sec><jats:sec><jats:title>Animals</jats:title><jats:p>A total of 244 client‐owned dogs reported by owners to be inappetent for at least 2 days were enrolled, with 177 cases in the effectiveness analysis.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>In this prospective, randomized, masked, placebo‐controlled study, dogs were treated daily with capromorelin (3 mg/kg) oral solution (n = 121) or placebo oral solution (n = 56). Owners completed an evaluation of appetite at days 0 and 3 ± 1. Success was defined as improvement in appetite at day 3. Safety was evaluated by physical examination, clinical pathology, and monitoring adverse events and owner observations.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Capromorelin treatment improved appetite compared to placebo (68.6% and 44.6% treatment successes with 95% CI 59.7, 76.3 and 32.2, 57.8, respectively, <jats:italic>P </jats:italic>=<jats:italic> </jats:italic>.008). Mean body weight in capromorelin‐treated dogs increased compared to placebo‐treated dogs (1.8% with 95% CI 1.3, 2.3, and 0.1% with 95% CI 0.9, 1.1, respectively, <jats:italic>P </jats:italic><<jats:italic> </jats:italic>.001). Adverse reactions occurring in >5% of either group were diarrhea and vomiting.</jats:p></jats:sec><jats:sec><jats:title>Conclusions and Clinical Importance</jats:title><jats:p>Capromorelin oral solution is an effective treatment for stimulation of appetite in dogs and represents the first ghrelin receptor agonist shown to be effective for this indication.</jats:p></jats:sec> |
| container_issue |
6 |
| container_start_page |
1851 |
| container_title |
Journal of Veterinary Internal Medicine |
| container_volume |
30 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792343105868922886 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:44:38.737Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=A+Prospective%2C+Randomized%2C+Masked%2C+Placebo%E2%80%90Controlled+Clinical+Study+of+Capromorelin+in+Dogs+with+Reduced+Appetite&rft.date=2016-11-01&genre=article&issn=1939-1676&volume=30&issue=6&spage=1851&epage=1857&pages=1851-1857&jtitle=Journal+of+Veterinary+Internal+Medicine&atitle=A+Prospective%2C+Randomized%2C+Masked%2C+Placebo%E2%80%90Controlled+Clinical+Study+of+Capromorelin+in+Dogs+with+Reduced+Appetite&aulast=Rhodes&aufirst=L.&rft_id=info%3Adoi%2F10.1111%2Fjvim.14607&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792343105868922886 |
| author | Zollers, B., Wofford, J.A., Heinen, E., Huebner, M., Rhodes, L. |
| author_facet | Zollers, B., Wofford, J.A., Heinen, E., Huebner, M., Rhodes, L., Zollers, B., Wofford, J.A., Heinen, E., Huebner, M., Rhodes, L. |
| author_sort | zollers, b. |
| container_issue | 6 |
| container_start_page | 1851 |
| container_title | Journal of Veterinary Internal Medicine |
| container_volume | 30 |
| description | <jats:sec><jats:title>Background</jats:title><jats:p>Reduced appetite is a common clinical sign in dogs. This study evaluated the effectiveness and safety of capromorelin oral solution, (ENTYCE<jats:sup>®</jats:sup>, Aratana Therapeutics, Leawood, KS) a new drug that is a ghrelin receptor agonist, for stimulation of appetite in dogs with reduced appetite.</jats:p></jats:sec><jats:sec><jats:title>Hypothesis/Objectives</jats:title><jats:p>Capromorelin will increase appetite, as measured by the owner's evaluation, over 4 days. An additional objective was to evaluate the safety of capromorelin at the labeled dose.</jats:p></jats:sec><jats:sec><jats:title>Animals</jats:title><jats:p>A total of 244 client‐owned dogs reported by owners to be inappetent for at least 2 days were enrolled, with 177 cases in the effectiveness analysis.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>In this prospective, randomized, masked, placebo‐controlled study, dogs were treated daily with capromorelin (3 mg/kg) oral solution (n = 121) or placebo oral solution (n = 56). Owners completed an evaluation of appetite at days 0 and 3 ± 1. Success was defined as improvement in appetite at day 3. Safety was evaluated by physical examination, clinical pathology, and monitoring adverse events and owner observations.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Capromorelin treatment improved appetite compared to placebo (68.6% and 44.6% treatment successes with 95% CI 59.7, 76.3 and 32.2, 57.8, respectively, <jats:italic>P </jats:italic>=<jats:italic> </jats:italic>.008). Mean body weight in capromorelin‐treated dogs increased compared to placebo‐treated dogs (1.8% with 95% CI 1.3, 2.3, and 0.1% with 95% CI 0.9, 1.1, respectively, <jats:italic>P </jats:italic><<jats:italic> </jats:italic>.001). Adverse reactions occurring in >5% of either group were diarrhea and vomiting.</jats:p></jats:sec><jats:sec><jats:title>Conclusions and Clinical Importance</jats:title><jats:p>Capromorelin oral solution is an effective treatment for stimulation of appetite in dogs and represents the first ghrelin receptor agonist shown to be effective for this indication.</jats:p></jats:sec> |
| doi_str_mv | 10.1111/jvim.14607 |
| facet_avail | Online, Free |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qdmltLjE0NjA3 |
| imprint | Wiley, 2016 |
| imprint_str_mv | Wiley, 2016 |
| institution | DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14 |
| issn | 0891-6640, 1939-1676 |
| issn_str_mv | 0891-6640, 1939-1676 |
| language | English |
| last_indexed | 2024-03-01T16:44:38.737Z |
| match_str | zollers2016aprospectiverandomizedmaskedplacebocontrolledclinicalstudyofcapromorelinindogswithreducedappetite |
| mega_collection | Wiley (CrossRef) |
| physical | 1851-1857 |
| publishDate | 2016 |
| publishDateSort | 2016 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Journal of Veterinary Internal Medicine |
| source_id | 49 |
| spelling | Zollers, B. Wofford, J.A. Heinen, E. Huebner, M. Rhodes, L. 0891-6640 1939-1676 Wiley General Veterinary http://dx.doi.org/10.1111/jvim.14607 <jats:sec><jats:title>Background</jats:title><jats:p>Reduced appetite is a common clinical sign in dogs. This study evaluated the effectiveness and safety of capromorelin oral solution, (ENTYCE<jats:sup>®</jats:sup>, Aratana Therapeutics, Leawood, KS) a new drug that is a ghrelin receptor agonist, for stimulation of appetite in dogs with reduced appetite.</jats:p></jats:sec><jats:sec><jats:title>Hypothesis/Objectives</jats:title><jats:p>Capromorelin will increase appetite, as measured by the owner's evaluation, over 4 days. An additional objective was to evaluate the safety of capromorelin at the labeled dose.</jats:p></jats:sec><jats:sec><jats:title>Animals</jats:title><jats:p>A total of 244 client‐owned dogs reported by owners to be inappetent for at least 2 days were enrolled, with 177 cases in the effectiveness analysis.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>In this prospective, randomized, masked, placebo‐controlled study, dogs were treated daily with capromorelin (3 mg/kg) oral solution (n = 121) or placebo oral solution (n = 56). Owners completed an evaluation of appetite at days 0 and 3 ± 1. Success was defined as improvement in appetite at day 3. Safety was evaluated by physical examination, clinical pathology, and monitoring adverse events and owner observations.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Capromorelin treatment improved appetite compared to placebo (68.6% and 44.6% treatment successes with 95% CI 59.7, 76.3 and 32.2, 57.8, respectively, <jats:italic>P </jats:italic>=<jats:italic> </jats:italic>.008). Mean body weight in capromorelin‐treated dogs increased compared to placebo‐treated dogs (1.8% with 95% CI 1.3, 2.3, and 0.1% with 95% CI 0.9, 1.1, respectively, <jats:italic>P </jats:italic><<jats:italic> </jats:italic>.001). Adverse reactions occurring in >5% of either group were diarrhea and vomiting.</jats:p></jats:sec><jats:sec><jats:title>Conclusions and Clinical Importance</jats:title><jats:p>Capromorelin oral solution is an effective treatment for stimulation of appetite in dogs and represents the first ghrelin receptor agonist shown to be effective for this indication.</jats:p></jats:sec> A Prospective, Randomized, Masked, Placebo‐Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite Journal of Veterinary Internal Medicine |
| spellingShingle | Zollers, B., Wofford, J.A., Heinen, E., Huebner, M., Rhodes, L., Journal of Veterinary Internal Medicine, A Prospective, Randomized, Masked, Placebo‐Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite, General Veterinary |
| title | A Prospective, Randomized, Masked, Placebo‐Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite |
| title_full | A Prospective, Randomized, Masked, Placebo‐Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite |
| title_fullStr | A Prospective, Randomized, Masked, Placebo‐Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite |
| title_full_unstemmed | A Prospective, Randomized, Masked, Placebo‐Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite |
| title_short | A Prospective, Randomized, Masked, Placebo‐Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite |
| title_sort | a prospective, randomized, masked, placebo‐controlled clinical study of capromorelin in dogs with reduced appetite |
| title_unstemmed | A Prospective, Randomized, Masked, Placebo‐Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite |
| topic | General Veterinary |
| url | http://dx.doi.org/10.1111/jvim.14607 |